# ADMA · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ADMA  
**Sources:** 30  
**Published:** 2026-08-06  
**Canonical:** https://app.k3vl4r.com/research/deep-research-adma-catalysts-narrative-risks-1633

---

# ADMA Biologics (ADMA) — Research Report as of August 27, 2026

## Company Overview

ADMA Biologics is a commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics. Its two key commercial products are **ASCENIV** (the flagship growth driver) and **BIVIGAM** (a standard intravenous immunoglobulin product facing competitive headwinds) [[6]](https://finance.yahoo.com/healthcare/articles/adma-biologics-inc-adma-q2-050926659.html)[[17]](https://ir.admabiologics.com/press-releases).

---

## Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-adma-catalysts-narrative-risks-1633 (free to sign up)._